CELC
NASDAQCelcuity
$87.43
-0.85 (-0.96%)
2026-06-08 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$4.60B
P/E Ratio
N/A
52W Low
52W High
$44.42
$151.02
Volume
1.4M
Analyst Rating
Hold
Target: $131
10 Analyst Ratings
Strong Buy
0
Buy
0
Hold
10
Sell
0
Price Target Range
Low: $110
Avg: $131
High: $169
About Celcuity
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...
Employees
155
Website
celcuity.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $154K | -111813.0% | -$177.0M | -$153.0M |
| 2024 | N/A | N/A% | -$111.8M | -$83.2M |
| 2023 | N/A | N/A% | -$63.8M | -$53.7M |
| 2022 | N/A | N/A% | -$40.4M | -$35.8M |
| 2021 | N/A | N/A% | -$29.6M | -$20.2M |
| 2026 Q1 | N/A | N/A% | -$52.8M | -$54.8M |
| 2025 Q4 | N/A | N/A% | -$51.0M | -$36.3M |
| 2025 Q3 | $154K | -27824.0% | -$43.8M | -$44.7M |
| 2025 Q2 | N/A | N/A% | -$45.3M | -$36.2M |
| 2025 Q1 | N/A | N/A% | -$37.0M | -$35.8M |
| 2024 Q4 | $121K | -30022.2% | -$36.7M | -$27.7M |
| 2024 Q3 | N/A | N/A% | -$29.8M | -$20.5M |
| 2024 Q2 | N/A | N/A% | -$23.7M | -$18.0M |